Hideki Takeshita

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

C. Porta, O. Fiala, J. Bellmunt, 2023, Cancer Immunology, Immunotherapy.

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

S. Salah, R. Kanesvaran, P. Giannatempo, 2024, Scientific reports.

Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.

O. Fiala, S. Salah, J. Bellmunt, 2023, Clinical and experimental medicine.

Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.

A. Poprach, S. Buti, R. Kanesvaran, 2024, Targeted oncology.